Kane Biotech Inc. announced that it has recently signed a distribution agreement with Salud Pharma S.A. (‘Salud Pharma') for its coactiv+™ Antimicrobial Hydrogel wound care and DermaKB™ scalp care products. Once Kane obtains 510(k) approval from the FDA, Salud Pharma through its distribution partners will register and commercialize Kane's coactiv+™ Antimicrobial wound gel throughout Colombia, Panama, and Costa Rica via wound care centers and pharmacies and will also import and distribute Kane's DermaKB™ line of scalp detoxifier and shampoos. The coactiv+™ Antimicrobial Hydrogel is a combination of Kane's patented coactiv+™ antibiofilm technology and PHMB in a thermo-reversible gel.

The combination of these three components provides for a moist environment best suited for wound healing, with superior anti-microbial activity in an easy-to-use thermo-reversible gelling system that is optimized for sensitive wounds. When the coactiv+™ Antimicrobial Wound Gel is cooled below 16° C/60° F, it transforms into a liquid state, allowing it to be poured onto a sensitive wound, such as a burn. Once applied, the product will gel within seconds, providing a thick clear coating.

It can then be easily rinsed off with cold water. The Company aims to make the wound gel accessible to patients, taking into consideration current reimbursement levels under the surgical dressing policy in the U.S. DermaKB™ Biofilm Products are a line of scalp care products with Kane's patented coactiv+™ technology that include scalp detoxifier, shampoo, and shampoo bar designed to break down biofilm. Recent research has indicated that the persistence of biofilms may be linked with aggravating the symptoms associated with common scalp conditions, such as dandruff and seborrheic dermatitis.

DermaKB™ ingredients are designated GRAS (Generally Recognized As Safe) by the FDA and suitable for daily use. Chronic wounds present a significant financial burden to the U.S. healthcare system. The treatment of chronic wounds is a major challenge for health care providers, with a high failure rate leading to amputation, sepsis, and death.

One of the major reasons for this failure is the formation of bacterial biofilms, which are present in over 80% of chronic wounds1. Biofilm formation can make bacteria up to 1,000 times more resistant to antibiotics, antimicrobial agents, disinfectants, and the host immune system.